NIH R01 · 2024
A platform for monitoring the efficacy and optimal dosing of long-acting ART
Project Summary/Abstract The rapidly emerging modalities of long-acting antiretroviral therapy (ART) for treatment and prevention are based on a one-size-fits-all dosing strategy despite these being our first experiences in real-world settings, where patient management challenges are common. To address this issue, we propose a novel pharmacologic monitoring platform for long-acting ART in real-world settings. We aim to develop and validate at-home self- collections and point-of-care (POC) testing for quantitative cabotegravir/rilpivirine (CAB/RPV) concentrations to support patient management and inform optimal use of long-acting ART and PrEP, with the vision that this platform will be…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.